EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ$6.52
Market Cap
$448.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
26 of 924
Rank in Industry
21 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
EYPT Insider Trading Activity
EYPT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $20,755,667 | 6 | 67 |
Sells | $383,745 | 3 | 33 |
Related Transactions
| Cormorant Asset Management, LP | 10 percent owner | 2 | $20.57M | 0 | $0 | $20.57M |
| Zaderej Karen L. | director | 1 | $99,750 | 0 | $0 | $99,750 |
| ANDO GORAN | director | 1 | $39,750 | 0 | $0 | $39,750 |
| Lurker Nancy | director | 1 | $25,003 | 0 | $0 | $25,003 |
| DICICCO WENDY F | director | 1 | $19,997 | 0 | $0 | $19,997 |
| GUYER DAVID R | director | 0 | $0 | 3 | $383,745 | $-383,745 |
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the …
Insider Activity of EyePoint Pharmaceuticals, Inc.
Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $20.76M and sold $383,745 worth of EyePoint Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $22.43M and sold $43.05M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $20.57M. Zaderej Karen L. (director) — $99,750. ANDO GORAN (director) — $39,750.
The last purchase of 5,000 shares for transaction amount of $39,750 was made by ANDO GORAN (director) on 2024‑08‑21.
List of Insider Buy and Sell Transactions, EyePoint Pharmaceuticals, Inc.
| 2024-08-21 | ANDO GORAN | director | 5,000 0.0082% | $7.95 | $39,750 | -8.56% | ||
| 2024-08-20 | DICICCO WENDY F | director | 2,567 0.0048% | $7.79 | $19,997 | +7.38% | ||
| 2024-08-19 | Zaderej Karen L. | director | 12,500 0.0235% | $7.98 | $99,750 | +4.22% | ||
| 2024-08-16 | Lurker Nancy | director | 3,173 0.0057% | $7.88 | $25,003 | +4.16% | ||
| 2024-07-12 | Sale | GUYER DAVID R | director | 11,625 0.0274% | $10.06 | $116,995 | -18.88% | |
| 2024-06-03 | Sale | GUYER DAVID R | director | 11,625 0.0233% | $10.30 | $119,705 | -13.16% | |
| 2024-05-14 | Sale | GUYER DAVID R | director | 11,625 0.0227% | $12.65 | $147,045 | -30.24% | |
| 2024-05-06 | Cormorant Asset Management, LP | 10 percent owner | 850,000 1.8064% | $11.86 | $10.08M | -22.28% | ||
| 2024-04-18 | Cormorant Asset Management, LP | 10 percent owner | 581,765 1.2029% | $18.03 | $10.49M | -50.00% | ||
| 2024-02-02 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 209 0.0007% | $28.49 | $5,954 | -67.70% | |
| 2024-01-26 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 26,017 0.0509% | $25.38 | $660,370 | -64.41% | |
| 2024-01-26 | Sale | Paggiarino Dario A. | Chief Medical Officer | 49,325 0.0975% | $25.66 | $1.27M | -64.41% | |
| 2024-01-25 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 600 0.0012% | $25.00 | $15,000 | -62.09% | |
| 2024-01-25 | Sale | Paggiarino Dario A. | Chief Medical Officer | 600 0.0012% | $25.00 | $15,000 | -62.09% | |
| 2024-01-24 | Sale | Lurker Nancy | Executive Vice Chair | 29,956 0.0887% | $24.98 | $748,250 | -60.48% | |
| 2024-01-24 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 11,300 0.0335% | $25.01 | $282,621 | -60.48% | |
| 2024-01-24 | Sale | Paggiarino Dario A. | Chief Medical Officer | 11,251 0.0334% | $25.01 | $281,415 | -60.48% | |
| 2024-01-23 | Sale | Lurker Nancy | Executive Vice Chair | 5,044 0.0144% | $24.97 | $125,950 | -61.98% | |
| 2024-01-23 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 900 0.0026% | $25.00 | $22,500 | -61.98% | |
| 2024-01-23 | Sale | Paggiarino Dario A. | Chief Medical Officer | 5,135 0.0146% | $25.00 | $128,375 | -61.98% |
Total: 82
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Cormorant Asset Management, LP | 10 percent owner | 8325000 12.1128% | $54.28M | 6 | 0 | <0.0001% |
| Lurker Nancy | director | 97635 0.1421% | $636,580.20 | 4 | 4 | <0.0001% |
| Zaderej Karen L. | director | 16500 0.024% | $107,580.00 | 1 | 0 | |
| ANDO GORAN | director | 13150 0.0191% | $85,738.00 | 1 | 0 | |
| DICICCO WENDY F | director | 9967 0.0145% | $64,984.84 | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,527,743 | 76 | 38.40% | $447.93M | |
$84,871,118 | 57 | 17.71% | $412.59M | |
$24,384,691 | 42 | -30.27% | $455.92M | |
$54,828,550 | 26 | -13.88% | $493.09M | |
$26,923,982 | 20 | -17.22% | $407.13M |
EYPT Institutional Investors: Active Positions
| Increased Positions | 95 | +77.87% | 22M | +37.34% |
| Decreased Positions | 49 | -40.16% | 6M | -10.54% |
| New Positions | 30 | New | 7M | New |
| Sold Out Positions | 23 | Sold Out | 2M | Sold Out |
| Total Postitions | 168 | +37.7% | 74M | +26.8% |
EYPT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Cormorant Asset Management, Lp | $52,198.00 | 12.24% | 8.32M | 0 | 0% | 2024-12-31 |
| Suvretta Capital Management, Llc | $42,530.00 | 9.98% | 6.78M | +2M | +31.05% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $36,053.00 | 8.46% | 5.75M | +2M | +51.66% | 2024-12-31 |
| Blackrock, Inc. | $33,114.00 | 7.77% | 5.28M | +1M | +27.1% | 2024-12-31 |
| Franklin Resources Inc | $25,943.00 | 6.09% | 4.14M | +125,519 | +3.13% | 2024-12-31 |
| Vanguard Group Inc | $23,846.00 | 5.59% | 3.8M | +755,045 | +24.77% | 2024-12-31 |
| Federated Hermes, Inc. | $23,246.00 | 5.45% | 3.71M | +2M | +92.73% | 2024-12-31 |
| Tcg Crossover Management, Llc | $22,399.00 | 5.25% | 3.57M | +3M | +287.31% | 2024-12-31 |
| Ra Capital Management, L.P. | $19,950.00 | 4.68% | 3.18M | +3M | New | 2024-12-31 |
| Citadel Advisors Llc | $15,467.00 | 3.63% | 2.47M | +1M | +75.28% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.